Evidence map›Paper›PMID 41201587›Full record

ArticleAnnals of hematology2025

Application of pretreatment

Xin Wen, Ang Wei, Guanyun Wang, Xia Lu, Ying Kan, Wei Wang, Rui Zhang, Jigang Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xin Wen *Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
Ang Wei *Hematology Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, 56 Nanlishi Road, Xicheng District, Beijing, 100045, China.
Guanyun Wang *Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
Xia LuNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
Ying KanNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
Wei WangNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
Rui ZhangHematology Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, 56 Nanlishi Road, Xicheng District, Beijing, 100045, China. ruizh1973@126.com.
Jigang YangNuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China. yangjigang@ccmu.edu.cn.

Funding

National Natural Science Foundation of China 82272034Natural Science Foundation of Beijing Municipality 7232031
6 · The paper itself

Abstract

To evaluate whether pre-treatment

Indexed as

Fluorodeoxyglucose F18Histiocytosis, Langerhans-CellPositron Emission Tomography Computed TomographyAdolescentChildChild, PreschoolFemaleHumansInfantMaleMutationPrognosisRetrospective StudiesFluorodeoxyglucose F1818F-FDG PET/CTCfBRAF V600E mutationLangerhans cell histiocytosisPediatricPrognosis

Identifiers

PMID41201587
PMCPMC12672597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.